PMHSOTCPharmaceutical PreparationsFiscal year ends December 31

Polomar Health Services, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026

$0.12−0.01 (-4.00%)

Close on Oct 19, 2026

Market cap: $3.37M
P/E (TTM): –
Dividend yield: –

Polomar Health Services, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31
Revenue	0.65	0.06	0.04	0.03
Cost of Revenue	0.19	0.03	0.00	–
Gross Profit	0.46	0.03	0.04	0.03
Selling, General & Admin	11	1.33	0.48	–
Selling & Marketing	0.07	0.05	0.03	–
General & Administrative	11	1.28	0.45	0.22
Operating Expenses	11	1.33	0.48	0.22
Operating Income	-11	-1.30	-0.44	-0.18
Interest Expense	0.15	0.04	0.00	–
Other Non-Operating Income	-0.15	-0.04	-0.15	0.00
Net Income	-11	-1.34	-0.59	-0.18
EPS (Basic)(per share)	-0.39	-0.05	-0.02	0.00
EPS (Diluted)(per share)	-0.39	-0.05	-0.02	0.00
Shares Outstanding (Basic, Weighted)(shares)	28	28	26	453
Shares Outstanding (Diluted, Weighted)(shares)	28	28	26	453
EBITDA	-0.78	-1.04	-0.43	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 61.1%
Operating margin: -295.0%
Net margin: -298.3%
Return on equity, FY2025: -290.1%

Financial strength

Current ratio: –
Debt to equity: –
Debt to assets: –
Cash to current liabilities: –

Valuation

P/E ratio: –
Price to sales: 1.06
Price to book: –
Dividend yield: –